Effect of Xuesaitong soft capsule on hemorrheology and in auxiliarily treating patients with acute cerebral infarction.
OBJECTIVE
To observe the therapeutic effect of Xuesaitong soft capsule (XST) and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI).


METHODS
Two hundred and four patients with ACI were assigned into two groups, the control group (n = 96) and the treated group (n = 108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8 successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrheological indexes were measured before and after treatment.


RESULTS
The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group (66.7%) was significantly higher than that in the control group (27.1%, P < 0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 in them evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups.


CONCLUSIONS
XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.
Zhong
Shang-qian
SQ
The Second People's Hospital of Liaocheng, Shandong. san123san@sina100.com
Sun
Li-jing
LJ
Yan
Yu-zhen
YZ
Sun
Yan-qin
YQ
Zhong
Yin-yuan
YY
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D001809:Blood Viscosity / Q000187:drug effects*; D002214:Capsules; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000503:physiopathology*; D003566:Cytidine Diphosphate Choline / Q000008:administration & dosage; D004234:Diuretics, Osmotic / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005260:Female; D006400:Hematocrit; D018056:Hemorheology; D006801:Humans; D008297:Male; D008353:Mannitol / Q000008:administration & dosage; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage; D010889:Piracetam / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage
D002214:Capsules; D004234:Diuretics, Osmotic; D004365:Drugs, Chinese Herbal; D018697:Nootropic Agents; D010975:Platelet Aggregation Inhibitors; D008353:Mannitol; D003566:Cytidine Diphosphate Choline; D001241:Aspirin; D010889:Piracetam